Sandoz on Monday announced the introduction of tobramycin inhalation solution, USP into the U.S. market. The drug is an authorized generic version of Tobi from Novartis.
Anacor Pharmaceuticals announced that the Food and Drug Administration has approved the company's new drug application for Kerydin (tavaborole) topical solution, 5% — an antifungal approved for the topical treatment of onychomycosis of the toenails.
A wave of new drug introductions and healthcare policy changes has had a significant impact on women’s health care over the past year.
Greenstone, a U.S.-based subsidiary of Pfizer, announced the introduction of doxazosin mesylate tablets.
Purdue Pharma on Tuesday announced that the Food and Drug Administration has granted priority review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet.
Mylan announced the launch of telmisartan tablets USP, which is used to treat hypertension.
NeuroMetrix on Tuesday announced that its wearable technology for treatment of chronic pain received 510(k) clearance from the Food and Drug Administration for over-the-counter use.
Novo Nordisk on Monday announced that the Food and Drug Administration approved the company's NovoSeven RT (coagulation factor VIIa [recombinant]).
Sandoz announced the launch of valsartan tablets, an authorized generic version of Diovan tablets which is used for the treatment of high blood pressure.
The Food and Drug Administration on Thursday announced approval for Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma.